Pierre Larochelle

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Lumenpulse, Inc. designs, develops, manufactures and sells a range of light emitting diode (LED) lighting products for commercial, institutional, and urban environments. It operates through the following segments: Lumenpulse Products and Other Manufactures Products. The Lumenpulse Products segment manufactures and sells lighting fixtures and solutions for indoor and outdoor applications with its primary focus on the commercial, institutional and urban environment markets. The Other Manufactures Products segment consist of products designed and manufactured by manufacturers other than the Company and can include both LED and traditional lighting fixtures. The firm offers lumenbeam LED projectors for applications in architectural exteriors and facades; lumenfacade LED luminaires for grazing, accenting, and floodlighting exterior and interior walls and facades; lumencove luminaires for installation on ledges and in coves; lumenline LED luminaires for architectural and commercial interiors. The company was founded by François-Xavier Souvay and Nicolas Bélanger in 2006 and is headquartered in Longueuil, Canada.

Picchio Pharma, Inc. engages in acquiring, developing, and commercializing new therapeutic products and technologies. The company was founded in 2001 and is headquartered in Laval, Canada.

Credit Suisse Securities (Canada) Inc. is a broker/dealer headquartered in Toronto, Ontario with offices worldwide. The firm is a subsidiary of Credit Suisse Group (NYSE: CS). Their equity research equity group engages in a broad range of activities for investors including sales, trading, financing, prime brokerage and market-making in U.S. and international equity and equity related securities, options, futures, risk management and hedging products. Their activities cover both exchange-traded and over-the-counter traded securities, including American depositary receipts, restricted stocks, equity repurchases, block trade executions, program trading executions, equity derivatives and convertible securities. The fixed-income franchise operates as a single, unified platform that handles all fixed-income cash and derivative products. Products and services range from securitization and liability management transactions to sales and trading and superior research.

Adaltis, Inc. is an international in-vitro diagnostic company. The company develops, manufactures and markets in-vitro diagnostic systems and reagent products to detect viral infections, diagnose immune system diseases and measure human hormone responses. Adaltis was founded on June 12, 1987 and is headquartered in Montreal, Canada.

Credit Suisse Securities (Europe) Ltd. (Credit Suisse Europe) is the Great Britain-based brokerage subsidiary of Credit Suisse Investment Holdings (UK), itself a subsidiary of Credit Suisse Group AG (SWX: CSGN) in Switzerland. The firm was founded in 1966 and formerly known as Credit Suisse First Boston (Europe) Ltd. Headquartered in London, Credit Suisse Europe arranges financing in international capital markets, provides financial advisory services and acts as a dealer in securities, derivatives and foreign exchange on a principal and agency basis for corporate and institutional investors.